Takeda buys Abbott’s stake in TAP
Executive Summary
Japanese drug maker Takeda will be the sole owner of TAP Pharmaceutical Products after the firm finalizes a deal March 19 to buy Abbott's share of the 50/50 joint venture. When the transaction closes, TAP will be integrated into Takeda Pharmaceuticals North America and Takeda Global Research & Development Center, with the two reporting to a newly established Takeda America Holdings. Takeda says the deal will make the company a top 15 pharmaceutical company in the U.S. As part of the deal, Abbott and Takeda will evenly divide the value of the joint venture, with Abbott maintaining the rights to the prostate cancer drug Lupron (leuprolide acetate). Takeda gets rights to the only other TAP-marketed product - the heartburn and gastro-esophageal reflux medication Prevacid (lansoprazole)
You may also be interested in...
Takeda’s Millennium Buy Brings In Potential Cancer Blockbuster Velcade
Takeda made an aggressive move toward its goal of becoming a top three oncology company with the acquisition of Millennium for $8.8 billion
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.